Switzerland becomes the fourteenth country to distribute Tilray's medical cannabis products.
Tilray, Inc. (NASDAQ: TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced it has successfully exported medical cannabis extracts to Switzerland.
Tilray's entry into Switzerland marks the fourteenth country to distribute Tilray's medical cannabis products, from its Good Manufacturing Practices (GMP)-certified production facility, to patients in need.
We're proud to deliver Tilray's medical cannabis to Swiss patients in need as we continue our expansion into Europe and around the globe. Sascha Mielcarek, Tilray's Managing Director in Europe
"Tilray is committed to quality and patient safety and we look forward to significantly improving the quality of lives of Swiss patients through our medical cannabis products," Mielcarek concluded.
The import and export permits were received in early December 2019, with the shipment of Tilray's medical cannabis extracts successfully arriving in Switzerland on December 13. Following this first shipment of extracts, Tilray also anticipates exporting dried medical cannabis to Switzerland, offering patients an assortment of form factors to meet their varying medical indications.
Last week, Tilray announced it received an additional GMP certification for its EU campus in Portugal, allowing the site to supply medical cannabis products to international patients, partners and markets. Tilray expects to supply its European partners from its EU campus in Cantanhede, Portugal beginning 2020.
To learn more about Tilray, visit their company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors